Zelluna ASA (OSTO:ULTIO) Short Percentage of Float


OSTO:ULTIO Zelluna ASA OSTO:ULTIO
28 GF Score
Price kr21.95
! 2 Warning Signs
View Full Analysis

What is Zelluna ASA Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

OSTO:ULTIO vs VRTX, REGN, ALNY: Short Percentage of Float Comparison

For the Biotechnology subindustry, Zelluna ASA's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Zelluna ASA Short Percentage of Float vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zelluna ASA's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Zelluna ASA's Short Percentage of Float falls into.


OSTO:ULTIO
28GF Score
Zelluna ASA OSTO:ULTIO
Short Percentage of Float is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Zelluna ASA Business Description

Other Exchanges ZLNA:Norway7UM0:Germany
Address Ullernchausseen 64, Oslo Cancer Cluster Innovation Park, Oslo, NOR, 0379
Zelluna ASA is a biotechnology company established to eliminate solid cancers by unleashing the powerful elements of the immune system through pioneering the development of T cell receptor (TCR) guided natural killer (NK) cell therapies (TCR-NK). Its TCR-NK products are composed of healthy donor-derived NK cells that are genetically engineered to express a tumour-specific TCR that enable the TCR-NK cells to identify and eliminate cancer cells in the body of the patient. Its programme ZI-MA4-1, the first MAGE-A4-targeting TCR-NK therapy for solid tumours with high unmet medical need. Its other programmes include ZI-KL1-1, and ZI-PR-1.
28GF Score

Get the complete analysis for OSTO:ULTIO

Short Percentage of Float is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr21.95
Price